ArticleThe American journal of psychiatry2013
The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders.
Article in The American journal of psychiatry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 214 papers, 15 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
214 citing papers in PubMed, 15 syntheses or guidelines pooled it, 744 citations in OpenAlex.
- Transdiagnostic efficacy of lurasidone on depressive symptoms: systematic review and meta-analysis of randomised controlled trials.The British journal of psychiatry : the journal of mental science · 2026Pooled it
- Systematic Review of Second-Generation Antidepressant Monotherapy for Acute Bipolar-II Depression.Psychopharmacology bulletin · 2025Pooled it
- Practice Guidelines for Bipolar Disorder by the JSMD (Japanese Society of Mood Disorders).Psychiatry and clinical neurosciences · 2024Guideline
- The Impact of Posttraumatic Stress Disorder on Pharmacologic Intervention Outcomes for Adults With Bipolar Disorder: A Systematic Review.The international journal of neuropsychopharmacology · 2023Pooled it
- A systematic review and meta-analysis of treatments for rapid cycling bipolar disorder.Acta psychiatrica Scandinavica · 2022Pooled it
- Ketamine's effect on inflammation and kynurenine pathway in depression: A systematic review.Journal of psychopharmacology (Oxford, England) · 2021Pooled it
- Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis.BMC psychiatry · 2021Pooled it
- Second Generation Antipsychotics Monotherapy as Maintenance Treatment for Bipolar Disorder: a Systematic Review of Long-Term Studies.The Psychiatric quarterly · 2020Pooled it
- Which Methodological Practice(s) for Psychotherapy Science? A Systematic Review and a Proposal.Integrative psychological & behavioral science · 2020Pooled it
- Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.Bipolar disorders · 2018Guideline
- Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews.BioMed research international · 2017Pooled it
- Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.Psychological medicine · 2016Pooled it
- Pooled it
- Mobile Apps for Bipolar Disorder: A Systematic Review of Features and Content Quality.Journal of medical Internet research · 2015Pooled it
- Management of adverse effects of mood stabilizers.Current psychiatry reports · 2015Pooled it
- Long-term safety and tolerability of lumateperone 42 mg in patients with bipolar disorder: results from a 6-month open-label extension study.International clinical psychopharmacology · 2026Trial
- Effect of medication therapy combined with transcranial direct current stimulation on depression and response inhibition of patients with bipolar disorder type I: a clinical trial.BMC psychiatry · 2021Trial
- Efficacy of Active vs Sham Intermittent Theta Burst Transcranial Magnetic Stimulation for Patients With Bipolar Depression: A Randomized Clinical Trial.JAMA network open · 2021Trial
- Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies.CNS spectrums · 2020Trial
- Efficacy and Safety of Transcranial Direct Current Stimulation as an Add-on Treatment for Bipolar Depression: A Randomized Clinical Trial.JAMA psychiatry · 2018Trial
154 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
67 authors at 1 institution in 1 country.
Funding
Abstract
objectiveThe risk-benefit profile of antidepressant medications in bipolar disorder is controversial. When conclusive evidence is lacking, expert consensus can guide treatment decisions. The International Society for Bipolar Disorders (ISBD) convened a task force to seek consensus recommendations on the use of antidepressants in bipolar disorders.
methodAn expert task force iteratively developed consensus through serial consensus-based revisions using the Delphi method. Initial survey items were based on systematic review of the literature. Subsequent surveys included new or reworded items and items that needed to be rerated. This process resulted in the final ISBD Task Force clinical recommendations on antidepressant use in bipolar disorder.
resultsThere is striking incongruity between the wide use of and the weak evidence base for the efficacy and safety of antidepressant drugs in bipolar disorder. Few well-designed, long-term trials of prophylactic benefits have been conducted, and there is insufficient evidence for treatment benefits with antidepressants combined with mood stabilizers. A major concern is the risk for mood switch to hypomania, mania, and mixed states. Integrating the evidence and the experience of the task force members, a consensus was reached on 12 statements on the use of antidepressants in bipolar disorder.
conclusionsBecause of limited data, the task force could not make broad statements endorsing antidepressant use but acknowledged that individual bipolar patients may benefit from antidepressants. Regarding safety, serotonin reuptake inhibitors and bupropion may have lower rates of manic switch than tricyclic and tetracyclic antidepressants and norepinephrine-serotonin reuptake inhibitors. The frequency and severity of antidepressant-associated mood elevations appear to be greater in bipolar I than bipolar II disorder. Hence, in bipolar I patients antidepressants should be prescribed only as an adjunct to mood-stabilizing medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.